Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 80Neoplasms 14Neoplasm Metastasis 14Brain Neoplasms 9Breast Neoplasms, Male 7Squamous Cell Carcinoma of Head and Neck 5Head and Neck Neoplasms 5Stomach Neoplasms 4Urinary Bladder Neoplasms 3Salivary Gland Neoplasms 3Recurrence 3Prostatic Neoplasms 3Inflammatory Breast Neoplasms 3Gallbladder Neoplasms 3Colorectal Neoplasms 3Carcinoma, Squamous Cell 3Carcinoma, Non-Small-Cell Lung 3Pancreatic Neoplasms 2Ovarian Neoplasms 2Glioma 2Glioblastoma 2Ependymoma 2Carcinoma, Ovarian Epithelial 2Carcinoma, Hepatocellular 2Bile Duct Neoplasms 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Tongue Neoplasms 1Thymoma 1Spinal Cord Neoplasms 1

Interventions

Exercise 2Trastuzumab 1N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine 1Lapatinib 1Diet 1Acupuncture Points 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Patient Compliance × Lapatinib × Clear all
NCT01273610 2025-06-10

Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer

City of Hope Medical Center

Phase 2 Active not recruiting
40 enrolled 15 charts
Breast

Breast Neoplasms, Patient Compliance

Data powered by HemOnc (CC BY 4.0) Colophon âš¡